Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on November 7, 2023, at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
10/31/2023 - 04:02 PM
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.
The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Corvus plans to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com .
INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522llea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750sseapy@realchemistry.com
When will Corvus Pharmaceuticals host a conference call and webcast?
Corvus Pharmaceuticals will host a conference call and webcast on November 7, 2023, at 4:30 pm ET (1:30 pm PT).
What is the purpose of the conference call and webcast?
The conference call and webcast will provide a business update and report second quarter 2023 financial results.
How can I access the conference call?
The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or via the investor relations section of the Corvus website.
Will there be a replay of the webcast?
Yes, a replay of the webcast will be available on Corvus' website for 90 days.
Corvus Pharmaceuticals Inc
CRVS Rankings
#678 Ranked by Stock Gains
CRVS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Burlingame
About CRVS
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.